Serena Tonstad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Serena Tonstad has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Ingebjørg Seljeflot
Center for Clinical Research, Ullevaal University Hospital, Oslo, Norway
2 shared publications- Kjetil Retterstøl
Department of Nutrition, Institute of Basic Medical Sciences University of Oslo Oslo Norway
2 shared publications Leiv Ose
Lipid Clinic, Rikshospitalet-Radiumhospitalet, N-0027 Oslo, Norway
2 shared publicationsTine Sundfør
2 shared publications- Tor Ole Klemsdal
Section for Preventive Cardiology, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
2 shared publications - Alison Mead
Imperial College London, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 9 March 2014
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (21) , 1411-1420
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial
The EUROACTION PLUS trial measured the effectiveness of a nurse-led preventive cardiology programme (EUROACTION) offering intensive smoking cessation PLUS optional varenicline for persistent high CVD risk smokers to reduce overall cardiovascular risk compared with usual care (UC) in general practice (GP). A parallel group randomized controlled trial in 20 GP in Italy, Netherlands, Spain, and UK. Six hundred and ninety-six current smokers, (137 vascular disease and 559 high total CVD risk), were randomized 350 to EUROACTION PLUS (EA+) and 346 to UC. Specially, trained nurses offered the EUROACTION preventive cardiology programme addressing smoking cessation, diet, physical activity, and risk factor management to reduce overall cardiovascular risk. The primary endpoint was 7 day point prevalence of self-reported abstinence (validated breath carbon monoxide <10 p.p.m.) at 16 weeks. Secondary outcomes included dietary habits, physical activity, weight, blood pressure (BP), lipid, and glucose management. One hundred and seventy-seven (51%) EA+ patients (91% opted to use varenicline) were abstinent vs. 63 (19%) in UC; OR 4.52 (95% CI: 3.20–6.39). The Mediterranean diet score of ≥9 in 149 (52%) EA+ patients vs. 97 (37%) in UC; OR 1.84 (95% CI: 1.31–2.59). Physical activity target achieved in 46 (16%) EA+ patients vs. 19 (7%) in UC; OR 2.48 (95% CI: 1.41–4.36). Target BP (<140/90 mm Hg) achieved in 150 (52%) EA+ patients vs. 112 (43%) in UC, OR 1.47 (95% CI: 1.05–2.06) with no difference in antihypertensive drugs. There were no differences in management of cholesterol or glucose. The EUROACTION preventive cardiology programme in high CVD risk smokers using optional varenicline substantially increased smoking abstinence over 16 weeks and also reduced overall cardiovascular risk compared with UC. REC reference: 09/H0402/85; EudraCT number: 2009-012451-18; http://www.controlled-trials.com/ISRCTN22073647, 12 February 2014, date last accessed.
- 9 March 2014
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (21) , 1411-1420
Open AccessEffectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial
The EUROACTION PLUS trial measured the effectiveness of a nurse-led preventive cardiology programme (EUROACTION) offering intensive smoking cessation PLUS optional varenicline for persistent high CVD risk smokers to reduce overall cardiovascular risk compared with usual care (UC) in general practice (GP). A parallel group randomized controlled trial in 20 GP in Italy, Netherlands, Spain, and UK. Six hundred and ninety-six current smokers, (137 vascular disease and 559 high total CVD risk), were randomized 350 to EUROACTION PLUS (EA+) and 346 to UC. Specially, trained nurses offered the EUROACTION preventive cardiology programme addressing smoking cessation, diet, physical activity, and risk factor management to reduce overall cardiovascular risk. The primary endpoint was 7 day point prevalence of self-reported abstinence (validated breath carbon monoxide <10 p.p.m.) at 16 weeks. Secondary outcomes included dietary habits, physical activity, weight, blood pressure (BP), lipid, and glucose management. One hundred and seventy-seven (51%) EA+ patients (91% opted to use varenicline) were abstinent vs. 63 (19%) in UC; OR 4.52 (95% CI: 3.20–6.39). The Mediterranean diet score of ≥9 in 149 (52%) EA+ patients vs. 97 (37%) in UC; OR 1.84 (95% CI: 1.31–2.59). Physical activity target achieved in 46 (16%) EA+ patients vs. 19 (7%) in UC; OR 2.48 (95% CI: 1.41–4.36). Target BP (<140/90 mm Hg) achieved in 150 (52%) EA+ patients vs. 112 (43%) in UC, OR 1.47 (95% CI: 1.05–2.06) with no difference in antihypertensive drugs. There were no differences in management of cholesterol or glucose. The EUROACTION preventive cardiology programme in high CVD risk smokers using optional varenicline substantially increased smoking abstinence over 16 weeks and also reduced overall cardiovascular risk compared with UC. REC reference: 09/H0402/85; EudraCT number: 2009-012451-18; http://www.controlled-trials.com/ISRCTN22073647, 12 February 2014, date last accessed.
- Open Access
- 8 March 2011
- Published by Springer Nature in Nutrition Journal
- Vol. 10 (1) , 21
Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders
Sleep related breathing disorders (SRBD) are associated with increased morbidity and mortality and weight loss is recommended to overweight or obese patients with SRBD. However, maintenance of weight loss is difficult to achieve and strategies for weight loss maintenance is needed. Orlistat is a pharmacological agent that reduces the intestinal absorption of fat and may favour long-term weight maintenance.
- 8 March 2011
- Published by Springer Nature in Nutrition Journal
- Vol. 10 (1) , 21
Open AccessOrlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders
Sleep related breathing disorders (SRBD) are associated with increased morbidity and mortality and weight loss is recommended to overweight or obese patients with SRBD. However, maintenance of weight loss is difficult to achieve and strategies for weight loss maintenance is needed. Orlistat is a pharmacological agent that reduces the intestinal absorption of fat and may favour long-term weight maintenance.
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (1) , 21-27
Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (1) , 21-27
Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia
- 29 October 2007
- Published by Springer Nature in International Journal of Obesity
- Vol. 31 (S2) , S19-S25
Identifying obese women most at risk from cardiovascular disease
- 29 October 2007
- Published by Springer Nature in International Journal of Obesity
- Vol. 31 (S2) , S19-S25
Identifying obese women most at risk from cardiovascular disease
- 30 September 2007
- Published by Elsevier in Metabolism
- Vol. 56 (9) , 1285-1292
The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
- 30 September 2007
- Published by Elsevier in Metabolism
- Vol. 56 (9) , 1285-1292
The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
- Open Access
- 12 July 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 154
Leisure time physical activity in middle age predicts the metabolic syndrome in old age: results of a 28-year follow-up of men in the Oslo study
Data are scarce on the long term relationship between leisure time physical activity, smoking and development of metabolic syndrome and diabetes. We wanted to investigate the relationship between leisure time physical activity and smoking measured in middle age and the occurrence of the metabolic syndrome and diabetes in men that participated in two cardiovascular screenings of the Oslo Study 28 years apart. Men residing in Oslo and born in 1923–32 (n = 16 209) were screened for cardiovascular diseases and risk factors in 1972/3. Of the original cohort, those who also lived in same area in 2000 were invited to a repeat screening examination, attended by 6 410 men. The metabolic syndrome was defined according to a modification of the National Cholesterol Education Program criteria. Leisure time physical activity, smoking, educational attendance and the presence of diabetes were self-reported. Leisure time physical activity decreased between the first and second screening and tracked only moderately between the two time points (Spearman's ρ = 0.25). Leisure time physical activity adjusted for age and educational attendance was a significant predictor of both the metabolic syndrome and diabetes in 2000 (odds ratio for moderately vigorous versus sedentary/light activity was 0.65 [95% CI, 0.54–0.80] for the metabolic syndrome and 0.68 [0.52–0.91] for diabetes) (test for trend P < 0.05). However, when adjusted for more factors measured in 1972/3 including glucose, triglycerides, body mass index, treated hypertension and systolic blood pressure these associations were markedly attenuated. Smoking was associated with the metabolic syndrome but not with diabetes in 2000. Physical activity during leisure recorded in middle age prior to the current waves of obesity and diabetes had an independent predictive association with the presence of the metabolic syndrome but not significantly so with diabetes 28 years later in life, when the subjects were elderly.
- 12 July 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 154
Open AccessLeisure time physical activity in middle age predicts the metabolic syndrome in old age: results of a 28-year follow-up of men in the Oslo study
Data are scarce on the long term relationship between leisure time physical activity, smoking and development of metabolic syndrome and diabetes. We wanted to investigate the relationship between leisure time physical activity and smoking measured in middle age and the occurrence of the metabolic syndrome and diabetes in men that participated in two cardiovascular screenings of the Oslo Study 28 years apart. Men residing in Oslo and born in 1923–32 (n = 16 209) were screened for cardiovascular diseases and risk factors in 1972/3. Of the original cohort, those who also lived in same area in 2000 were invited to a repeat screening examination, attended by 6 410 men. The metabolic syndrome was defined according to a modification of the National Cholesterol Education Program criteria. Leisure time physical activity, smoking, educational attendance and the presence of diabetes were self-reported. Leisure time physical activity decreased between the first and second screening and tracked only moderately between the two time points (Spearman's ρ = 0.25). Leisure time physical activity adjusted for age and educational attendance was a significant predictor of both the metabolic syndrome and diabetes in 2000 (odds ratio for moderately vigorous versus sedentary/light activity was 0.65 [95% CI, 0.54–0.80] for the metabolic syndrome and 0.68 [0.52–0.91] for diabetes) (test for trend P < 0.05). However, when adjusted for more factors measured in 1972/3 including glucose, triglycerides, body mass index, treated hypertension and systolic blood pressure these associations were markedly attenuated. Smoking was associated with the metabolic syndrome but not with diabetes in 2000. Physical activity during leisure recorded in middle age prior to the current waves of obesity and diabetes had an independent predictive association with the presence of the metabolic syndrome but not significantly so with diabetes 28 years later in life, when the subjects were elderly.
- 22 June 2007
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 6 (2) , 160-164
Effect of Nurse Counselling on Metabolic Risk Factors in Patients with Mild Hypertension: A Randomised Controlled Trial
Hypertension often clusters with metabolic risk factors and its optimal treatment may involve a number of changes in lifestyle. Nurse-led care regarding lifestyle change may improve outcomes in cardiovascular disease prevention involving. To examine if lifestyle guidance given by a nurse improved components of the metabolic syndrome including blood pressure, lipids and waist circumference. Subjects that participated in a health screening with systolic blood pressure 140-169 mm Hg and diastolic blood pressure 90-99 mm Hg at a minimum of three separate readings treated or not treated with antihypertensive drugs were randomly allocated either to monthly nurse-led lifestyle counselling (intervention group, N=31) or to conventional primary care (control group, N=20) to be followed by lifestyle counselling. The mean (S.D.) baseline and end of study blood pressure was 157 (9)/94 (6) mm Hg and 147 (9)/91 (8) mm Hg, respectively, in the intervention group versus 153 (9)/94 (4) and 143 (10)/92 (8) mm Hg, respectively, in the control group (NS between the groups). Waist circumference increased significantly between baseline and 6 months in the control but not in the intervention (mean difference between the groups, 3.1 cm [95% CI 1.2-5.0], p=0.04) and serum triglyceride concentrations were reduced in the intervention compared with the control group (mean difference, 0.56 mmol/l [95% CI 0.22-0.90], p=0.03). The number of risk factors of the metabolic syndrome was 2.1 (S.D. 1.1) at baseline and 2.6 (S.D. 1.2) at 6 months in the control group versus 2.2 (S.D. 1.1) and 1.9 (S.D. 1.0), respectively, in the intervention group (p=0.01). Change in triglycerides was correlated with change in weight (Pearson's correlation coefficient=0.73, p=0.001) and waist circumference (Pearson's correlation coefficient=0.63, p=0.009) in the control group. Nurse counselling did not reduce blood pressure but was associated with a lesser gain in waist circumference and reduced triglyceride concentrations. Metabolic risk factors may worsen rapidly in patients with mild hypertension in the waiting period for lifestyle intervention.
- 22 June 2007
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 6 (2) , 160-164
Effect of Nurse Counselling on Metabolic Risk Factors in Patients with Mild Hypertension: A Randomised Controlled Trial
Hypertension often clusters with metabolic risk factors and its optimal treatment may involve a number of changes in lifestyle. Nurse-led care regarding lifestyle change may improve outcomes in cardiovascular disease prevention involving. To examine if lifestyle guidance given by a nurse improved components of the metabolic syndrome including blood pressure, lipids and waist circumference. Subjects that participated in a health screening with systolic blood pressure 140-169 mm Hg and diastolic blood pressure 90-99 mm Hg at a minimum of three separate readings treated or not treated with antihypertensive drugs were randomly allocated either to monthly nurse-led lifestyle counselling (intervention group, N=31) or to conventional primary care (control group, N=20) to be followed by lifestyle counselling. The mean (S.D.) baseline and end of study blood pressure was 157 (9)/94 (6) mm Hg and 147 (9)/91 (8) mm Hg, respectively, in the intervention group versus 153 (9)/94 (4) and 143 (10)/92 (8) mm Hg, respectively, in the control group (NS between the groups). Waist circumference increased significantly between baseline and 6 months in the control but not in the intervention (mean difference between the groups, 3.1 cm [95% CI 1.2-5.0], p=0.04) and serum triglyceride concentrations were reduced in the intervention compared with the control group (mean difference, 0.56 mmol/l [95% CI 0.22-0.90], p=0.03). The number of risk factors of the metabolic syndrome was 2.1 (S.D. 1.1) at baseline and 2.6 (S.D. 1.2) at 6 months in the control group versus 2.2 (S.D. 1.1) and 1.9 (S.D. 1.0), respectively, in the intervention group (p=0.01). Change in triglycerides was correlated with change in weight (Pearson's correlation coefficient=0.73, p=0.001) and waist circumference (Pearson's correlation coefficient=0.63, p=0.009) in the control group. Nurse counselling did not reduce blood pressure but was associated with a lesser gain in waist circumference and reduced triglyceride concentrations. Metabolic risk factors may worsen rapidly in patients with mild hypertension in the waiting period for lifestyle intervention.
- 1 February 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (2) , 121-127
Varenicline for smoking cessation
Varenicline is a selective alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist and the first non-nicotine-containing medication developed with the sole purpose of treating nicotine addiction. To date, four published clinical trials have demonstrated the efficacy and safety of varenicline for smoking cessation in healthy adults who were ready to make a quit attempt. One additional trial found that extended use of varenicline effectively reduced relapse to smoking. One trial to date published as a poster documented the 1-year safety of the drug. Varenicline was more efficacious than bupropion 24 weeks after randomization to a 12-week treatment course and 1 year after randomization in an identical trial. It has no contraindications except hypersensitivity and is well tolerated. This article reviews the available information on varenicline and discusses its clinical use.
- 1 February 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (2) , 121-127
Varenicline for smoking cessation
Varenicline is a selective alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist and the first non-nicotine-containing medication developed with the sole purpose of treating nicotine addiction. To date, four published clinical trials have demonstrated the efficacy and safety of varenicline for smoking cessation in healthy adults who were ready to make a quit attempt. One additional trial found that extended use of varenicline effectively reduced relapse to smoking. One trial to date published as a poster documented the 1-year safety of the drug. Varenicline was more efficacious than bupropion 24 weeks after randomization to a 12-week treatment course and 1 year after randomization in an identical trial. It has no contraindications except hypersensitivity and is well tolerated. This article reviews the available information on varenicline and discusses its clinical use.
- 1 February 2007
- Published by Elsevier in Metabolism
- Vol. 56 (2) , 260-266
Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease?
- 1 February 2007
- Published by Elsevier in Metabolism
- Vol. 56 (2) , 260-266
Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease?
- 4 January 2007
- Vol. 127 (1) , 50-3
[Nutritional status after surgical treatment of obesity].
Biliopancreatic bypass with duodenal switch is a treatment for morbid obesity that combines restriction of dietary intake with a high degree of malabsorption. The operation involves the risk of losing important nutritional elements. 64 women and 14 men who had a biliopancreatic bypass with duodenal switch performed in 2002 - 2005 and were followed up at least once, six months or later after surgery, were examined with 3 to 6-month intervals for the following; body weight, clinical status, haematological variables, ferritin, folate, albumin, creatinine, retinol, alpha-tocopherol/lipids, vitamin D metabolites, parathyroid hormone, vitamin B1, lipids, glucose and other clinical chemical variables. Weight loss after surgery was substantial and rapid, from a mean of 153.8 kg (SD 30.2) to 92.7 kg (SD 21.6) after one year (n = 74). Low values of serum albumin, creatinine, retinol, 25-OH vitamin D and elevated parathyroid hormone were very common. Four women and three men (9 % of all) with common channels of < 100 cm, required a surgical revision mainly due to hypoalbuminemia. Two women became pregnant before the recommended 18 months after surgery. Biliopancreatic bypass with duodenal switch in patients with common channels < 100 cm, has a high rate of complications and nutritional deficiencies. This surgery should be used restrictively.
- 4 January 2007
- Vol. 127 (1) , 50-3
[Nutritional status after surgical treatment of obesity].
Biliopancreatic bypass with duodenal switch is a treatment for morbid obesity that combines restriction of dietary intake with a high degree of malabsorption. The operation involves the risk of losing important nutritional elements. 64 women and 14 men who had a biliopancreatic bypass with duodenal switch performed in 2002 - 2005 and were followed up at least once, six months or later after surgery, were examined with 3 to 6-month intervals for the following; body weight, clinical status, haematological variables, ferritin, folate, albumin, creatinine, retinol, alpha-tocopherol/lipids, vitamin D metabolites, parathyroid hormone, vitamin B1, lipids, glucose and other clinical chemical variables. Weight loss after surgery was substantial and rapid, from a mean of 153.8 kg (SD 30.2) to 92.7 kg (SD 21.6) after one year (n = 74). Low values of serum albumin, creatinine, retinol, 25-OH vitamin D and elevated parathyroid hormone were very common. Four women and three men (9 % of all) with common channels of < 100 cm, required a surgical revision mainly due to hypoalbuminemia. Two women became pregnant before the recommended 18 months after surgery. Biliopancreatic bypass with duodenal switch in patients with common channels < 100 cm, has a high rate of complications and nutritional deficiencies. This surgery should be used restrictively.